REVIEWS far feasible.This point with multipl ch in ses such nty of the coml activation of the molecular target in their tumour,as also being investigated o ST1-571 ST-57I 02 47. 21641 -2298 ,ag0a 61221-22E133 d he (P N M 34. 2) ang BOR-AB 1188121 CR- of the M& . LUME 2002 Nature Publishing Grour© 2002 Nature Publishing Group NATURE REVIEWS | DRUG DISCOVERY VOLUME 1 | JULY 2002 | 501 REVIEWS far as is technically feasible. This point has been cru￾cial in the successful outcome of the CML, GIST and CMML trials. The activity of Glivec in more common cancers with multiple and more complex molecular abnormalities remains to be determined, and is the objective of continuing research in diseases such as SCLC, prostate cancer and gliomas. The potential activity of the combination of Glivec with other sig￾nal-transduction inhibitors or anticancer agents is also being investigated. pathways, or through targeting of the tumour micro￾environment. However, most human cancers are likely to be heterogeneous with regard to molecular abnor￾malities, such as oncogene activation, and involve multiple signalling pathways in addition to either c￾KIT and/or the PDGFR. Consequently, careful atten￾tion will have to be paid in designing clinical trials in these more complex indications as to how patients should be selected on the basis of the expression or activation of the molecular target in their tumour, as 1. Rowley, J. D. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature 243, 290–293 (1973). 2. Nowell, P. C. & Hungerford, D. A. A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497 (1960). 3. Daley, G. Q., Van Etten, R. A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the p210Bcr/Abl gene of the Philadelphia chromosome. Science 247, 824–830 (1990). 4. Kelliher, M. A. et al. Induction of chronic myelogenous leukemia in mice by the v-Abl and Bcr/Abl. Proc. Natl Acad. Sci. USA 87, 6649–6653 (1990). 5. Heisterkamp, N. et al. Acute leukaemia in Bcr/Abl transgenic mice. Nature 344, 251–253 (1990). 6. Lugo, T. G. et al. Tyrosine kinase activity and transformation potency of Bcr–Abl oncogene products. Science 247, 1079–1082 (1990). 7. Lipinsky, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44, 235–249 (2001). 8. Teague, S. et al. The design of leadlike combinatorial libraries. Angew. Chem. Int. Edn Eng. 38, 3743–3748 (1999). 9. Zimmermann, J. et al. (Phenylamino)pyrimidine (PAP) derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg. Med. Chem. Lett. 6, 1221–1226 (1996). 10. Zimmermann, J. et al. Potent and selective inhibitors of the ABL-kinase: phenylaminopyrimidine (PAP) derivatives. Bioorg. Med. Chem. Lett. 7, 187–192 (1997). 11. Zimmerman, J., Furet, P. & Buchdunger, E. STI571. A new treatment modality for CML. ACS Symp. Ser. 796, 245–259 (2001). 12. Schindler, T. et al. Structural mechanism for STI571 inhibition of Abelson tyrosine kinase. Science 289, 1938–1942 (2000). The first description of the structural interactions between Glivec and ABL using crystallographic studies. Provided an important insight into potential mechanisms of resistance. 13. Okuda, K. et al. ARG tyrosine kinase activity is inhibited by STI571. Blood 97, 2440–2448 (2001). 14. Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells. Nature Med. 2, 561–566 (1996). The first study to document the strong efficacy of Glivec in in vitro and in vivo models of BCR–ABL￾positive leukaemias. 15. Carroll, M. et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR–ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90, 4947–4952 (1997). 16. Beran, M. et al. Selective inhibition of cell proliferation and BCR–ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR–ABL protein by a tyrosine kinase inhibitor (CGP 57148). Clin. Cancer Res. 4, 1661–1672 (1998). 17. Gambacorti-Passerini, C. et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol. Dis. 23, 380–394 (1997). 18. Deininger, M. et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR–ABL-positive cells. Blood 90, 3691–3698 (1997). 19. Dan, S., Naito, M. & Tsuruo, T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148B. Cell Death Differ. 5, 710–715 (1998). 20. Le Coutre, P. et al. In vivo eradication of human BCR/ABL￾positive leukemia cells with an ABL kinase inhibitor. J. Natl Cancer Inst. 91, 163–168 (1999). 21. Wolff, N. C. & Ilaria, R. L. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood 98, 2808–2816 (2001). 22. Sillaber, C. et al. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 95, 2118–2125 (2000). 23. Horita, M. et al. Blockade of the Bcr–Abl kinase activity induces apoptosis of chronic myeloid leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of BCL-XL . J. Exp. Med. 191, 977–984 (2000). 24. Oda, T. et al. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J. Biol. Chem. 269, 22925–22928 (1994). 25. Jonuleit, T. et al. Bcr–Abl kinase downregulates cyclin￾dependent kinase inhibitor p27 in human and murine cell lines. Blood 96, 1933–1939 (2000). 26. Gesbert, F. et al. BCR/ABL regulates expression of the cyclin dependent kinase inhibitor p27Kip1 through the PI3K/AKT pathway. J. Biol. Chem. 50, 39223–39230 (2000). 27. Gaston, I. et al. Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr–Abl transformed cells. Exp. Hematol. 28, 77–86 (2000). 28. Druker, B. J. et al. Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038–1042 (2001). The first clinical results with Glivec in CML, documenting a high level of efficacy, low level of toxicity and describing the dose–response relationship. These results confirm the crucial role of BCR–ABL in the pathophysiology of CML. 29. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001). 30. Peng, B. et al. Clinical investigation of the PK/PD relationship for Glivec (STI571): a novel inhibitor of signal transduction. Proc. Am. Soc. Clin. Oncol. 20, 280 (2001). 31. Kantarjian, H. et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645–652 (2002). 32. Talpaz, M. et al. Glivec™ (imatinib mesylate) induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase 2 study. Blood 99, 1928–1937 (2002). 33. Sawyers, C. et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a Phase II study. Blood 99, 3530–3539 (2002). 34. Weisberg, E. & Griffin, J. Mechanism of resistance to the Abl tyrosine kinase inhibitor STI571in BCR/ABL transformed hematopoietic cell lines. Blood 95, 3498–3505 (2000). 35. Mahon, F. et al. Selection and characterization of BCR–ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96, 1070–1079 (2000). 36. Le Coutre, P. et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95,1758–1766 (2000). 37. Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science 293, 876–880 (2001). This study describes potential mechanisms of resistance in CML in clinical samples from treated patients. 38. Gorre, M. E. et al. Roots of clinical resistance to STI-571 cancer therapy. Science 293, 2163a (2001). 39. Barthe, C. et al. Roots of clinical resistance to STI-571 cancer therapy. Science 293, 2163a (2001). 40. Hochhaus, A. et al. Roots of clinical resistance to STI-571 cancer therapy. Science 293, 2163a (2001). 41. Von Bubnoff, N. et al. BCR–ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359, 487–491 (2002). 42. Manley, P. W. et al. Molecular interactions between Gleevec™ and isoforms of the c-Abl kinase. Proc. Am. Assoc. Cancer Res. 4196 (2002). 43. Gambacorti-Passerini, C. et al. α1 Acidic glycoprotein (AGP) binds, inhibits and causes in vivo resistance of human BCR–ABL+ leukemic cells to STI571. J. Natl Cancer Inst. 92, 1641–1650 (2000). 44. Jorgensen, H. G. et al. α1 -Acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood 99, 713–715 (2002). 45. Hofmann, W. K. et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene￾expression profiles: a gene-expression study. Lancet 359, 481–486 (2002). 46. Druker, B. STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN)+ cytarabine as initial therapy for patients with CML: results of a randomized study. Proc. Am. Soc. Clin. Oncol.1 (2002). 47. Buchdunger, E. et al. The Abl protein-tyrosine kinase inhibitor, STI571, inhibits in vitro signal transduction mediated by c-Kit and PDGF receptors. J. Pharmacol. Exp. Ther. 295, 139–145 (2000). 48. Heinrich, M. C. et al. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood 96, 925–932 (2000). 49. Hirota, S. et al. Gain of function mutations of c-Kit in human gastrointestinal stromal tumors. Science 279, 577–580 (1998). This study establishes the importance of c-KIT signalling in the pathogenesis of GIST tumours. 50. Lasota, J. et al. Mutations in exons 9 and 13 of Kit gene are rare events in gastrointestinal stromal tumors. A study of two hundred cases. Am. J. Pathol. 157, 1091–1095 (2000). 51. Lux, M. L. et al. Kit extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am. J. Pathol. 156, 791–795 (2000). 52. Rubin, B. P. et al. Kit activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61, 8118–8121 (2001). 53. Heinrich, M. C. et al. STI571 inhibits the kinase activity of wild type and juxtamembrane c-Kit mutants but not the exon 17 D816V mutations associated with mastocytosis. Blood 96, 4459 (2000). 54. Tuveson, D. A. et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20, 5054–5058 (2001). 55. Joensuu, H. et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344, 1052–1056 (2001). A proof-of-concept report of the efficacy of Glivec in KIT-expressing GIST, and rationale for further development in this indication, as well as in other solid tumours that express KIT. 56. Van Oosterom, A. T. et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors, a phase I study. Lancet 358, 1421–1423 (2001)